What one share of REVIUM Rx. holds
We are a pre-clinical stage biopharmaceutical company focused on the development and eventual commercialization of innovative and proprietary nanoparticle-based therapies. We focus on creating smarter, more targeted treatments that improve how medicines work in the body, with the goal of increasing effectiveness while reducing side effects.
REVIUM Rx.’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.22 |
|---|---|
| Cash and investments | $0.01 |
| Book value | $0.09 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2025 | — | −$0.22 | — | — | — | $0.11 |
Common questions about REVIUM Rx.
How much does one share of REVIUM Rx. earn?
Over the last 12 months, REVIUM Rx. lost $0.22 for each share.
Does REVIUM Rx. pay a dividend?
REVIUM Rx. didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is REVIUM Rx.’s book value per share?
REVIUM Rx.’s book value is $0.09 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of REVIUM Rx. have?
Each share of REVIUM Rx. has $0.01 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.